Biogen's EU setback highlights importance of research, says Alzheimer's organization
The expected EU rejection of Biogen's Alzheimer's drug has put a focus on the importance of dementia research, and may incentivize other pharmaceutical companies to throw their hats into the ring, says the head of the Danish non-profit Alzheimer's organization, Alzheimerforeningen. A professor of dementia also predicts a future need for earlier disease tracing, should Aduhelm be approved in Denmark.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY DANIEL PEDERSEN
Although the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) giving the company's Alzheimer's drug Aduhelm (aducanumab) the thumbs-down in a trend vote on Wednesday was a spanner in the works for Biogen, there might still be a silver lining for the company.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Biogen passes FDA test for Alzheimer's medicine
For subscribers
Biogen's Alzheimer's drug Aduhelm faces EU rejection
For subscribers
.jpg&w=384&q=75)
